Crystalline Forms of 1-(4-benzyloxy-benzyl)-3-methyl-thiourea for Pharmaceutical Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing compounds of 1-(4-benzyloxy-benzyl)-3-methyl-thiourea lack stable crystalline forms, which are essential for pharmaceutical applications due to issues with stability and purity, making them unsuitable for commercialization and mass production.
Innovation Solution
Development of crystalline forms A, B, and C, along with an amorphous form of 1-(4-benzyloxy-benzyl)-3-methyl-thiourea, characterized by specific powder X-ray diffraction patterns and preparation methods using various solvents and anti-solvents, enhancing stability and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If column purification is performed to increase purity, then purity is improved, but manufacturing complexity and cost increase making it unsuitable for mass production
Solution Approach 1:
The patent changes the physical state parameter of the compound from amorphous to crystalline form. This parameter change enables the compound to be purified through crystallization rather than requiring complex column purification, thereby maintaining high purity while simplifying the manufacturing process for mass production
Solution Approach 2:
The patent utilizes phase transition from amorphous to crystalline form to achieve purification. The crystalline form naturally separates from impurities during the crystallization process, eliminating the need for column purification and enabling scalable manufacturing
2Reliability
If crystalline forms are developed for pharmaceutical applications, then stability and purity are improved, but the complexity of characterizing and controlling different crystalline forms increases
Solution Approach 1:
The patent focuses on developing specific crystalline forms with particular properties (crystalline form A, B, and C) rather than attempting to control all possible crystalline forms. Each crystalline form is characterized by specific PXRD patterns, allowing targeted development of forms with desired stability profiles while managing characterization complexity through focused selection
Solution Approach 2:
The patent changes the physical form parameter from amorphous to specific crystalline forms (A, B, C) with defined PXRD patterns. This parameter change improves stability while the discrete nature of specific crystalline forms simplifies characterization compared to controlling a continuum of possible crystalline structures
3Ease of manufacture
If amorphous form is used, then ease of manufacture is improved, but stability and storage properties deteriorate
Solution Approach 1:
The patent utilizes phase transition from amorphous to crystalline form to improve storage stability. The crystallization process maintains ease of manufacture through straightforward crystallization procedures while the resulting crystalline structure provides enhanced stability and storage properties
Solution Approach 2:
The patent changes the physical state parameter from amorphous to crystalline, which improves storage stability while maintaining manufacturing simplicity through crystallization processes that are easier to control and scale than maintaining amorphous forms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new crystalline forms exhibit improved physical and chemical stability, including storage stability and non-hygroscopic properties, facilitating long-term use in pharmaceutical preparations for treating metabolic and inflammatory diseases, and enabling economically feasible industrial production without the need for column purification.
Implementation Method 1
Development of crystalline forms A, B, and C, along with an amorphous form of 1-(4-benzyloxy-benzyl)-3-methyl-thiourea, characterized by specific powder X-ray diffraction patterns and preparation methods using various solvents and anti-solvents
Implementation Method 2
crystalline forms A, B, and C, along with an amorphous form of 1-(4-benzyloxy-benzyl)-3-methyl-thiourea, characterized by specific powder X-ray diffraction patterns
Data Source
AI summary
The present disclosure relates to a 1-(4-benzyloxy-benzyl)-3-methyl-thiourea compound in crystalline forms A, B, C, or amorphous form, a method for preparing the compound in the crystalline or amorphous forms, and a use of the compound for preventing or treating a metabolic disease or inflammatory disease.